Zobrazeno 1 - 10
of 29
pro vyhledávání: '"MIAOLIN ZHU"'
Autor:
Ruotong Wang, Shaodi Wen, Xiaoyue Du, Jingwei Xia, Bowen Hu, Yihan Zhang, Guoren Zhou, Feng Jiang, Xiaomin Lu, Miaolin Zhu, Xinyu Xu, Bo Shen
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background Despite the recognized therapeutic potential of programmed cell death protein 1/programmed death‐ligand 1 (PD‐1/PD‐L1) inhibitors in advanced esophageal squamous cell carcinoma (ESCC), their role in neoadjuvant therapy and r
Externí odkaz:
https://doaj.org/article/64bab336fbf5471fb8f1066ac0688b52
Autor:
Yue Wang, Ying Li, Liang Wang, Buze Chen, Miaolin Zhu, Chunyi Ma, Chunyan Mu, Aibin Tao, Shibao Li, Lan Luo, Ping Ma, Shuai Ji, Ting Lan
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/6c3e4bd35f224880965f65cfb5066c7f
Autor:
Shaodi Wen, Renrui Zou, Xiaoyue Du, Rongtian Pan, Rutao Li, Jingwei Xia, Cong Xu, Ruotong Wang, Feng Jiang, Guoren Zhou, Jifeng Feng, Miaolin Zhu, Xin Wang, Bo Shen
Publikováno v:
Heliyon, Vol 10, Iss 6, Pp e27170- (2024)
Background: Malignant tumours, particularly non-small cell lung cancer (NSCLC), pose a significant threat to human health due to their prevalence and lethality. Treatment methods for NSCLC vary greatly among individuals, making it crucial to identify
Externí odkaz:
https://doaj.org/article/dbdb03007d0d4b31ae0cdb682cf95fc5
Autor:
Fengfeng Han, Shuwei Guo, Chao Huang, Linjing Cui, Yuanyuan Zhao, Jie Ma, Miaolin Zhu, Zhihong Chen, Mei Wang, Bo Shen, Wei Zhu
Publikováno v:
Central European Journal of Immunology, Vol 46, Iss 4, Pp 427-437 (2021)
Externí odkaz:
https://doaj.org/article/57d027d3c6b04ff486c537626913e262
Autor:
Yue Wang, Ying Li, Liang Wang, Buze Chen, Miaolin Zhu, Chunyi Ma, Chunyan Mu, Aibin Tao, Shibao Li, Lan Luo, Ping Ma, Shuai Ji, Ting Lan
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Ovarian cancer is one of the most common gynecological malignancies in women worldwide with a poor survival rate. Cinnamaldehyde (CA), a bioactive substance isolated from cinnamon bark, is a natural drug and has shown that it can inhibit the progress
Externí odkaz:
https://doaj.org/article/ad23d7339484453c81f9c0dadb869fb4
Autor:
Shaodi Wen, Yuzhong Chen, Chupeng Hu, Xiaoyue Du, Jingwei Xia, Xin Wang, Wei Zhu, Qingbo Wang, Miaolin Zhu, Yun Chen, Bo Shen
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
BackgroundHepatocellular carcinoma (HCC) is the most common pathological type of primary liver cancer. The lack of prognosis indicators is one of the challenges in HCC. In this study, we investigated the combination of tertiary lymphoid structure (TL
Externí odkaz:
https://doaj.org/article/84eee63a27a54261b27e3aaa3c7d5aba
Autor:
Yan Wu, Min Wu, Zibin Wang, Ji Pang, Miaolin Zhu, Ting Lan, Xiaoyuan Yao, Hai Qian, Xinyue Lin, Lu Jiang, Yan Tao, Yujie Zhang, Yongchang Chen
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 27, Iss 2, p 053 (2022)
Background: Protein kinase G type II (PKG II) is a serine/threonine-protein kinase that was originally isolated from the small intestinal mucosa with primary functions in the secretion of small intestinal mucosal cells, secretion of renin and aldoste
Externí odkaz:
https://doaj.org/article/879749b1ab9e4433b6a8e0e39c7787f4
Autor:
Yan Wu, Miaomiao Yuan, Wenbin Su, Miaolin Zhu, Xiaoyuan Yao, Ying Wang, Hai Qian, Lu Jiang, Yan Tao, Min Wu, Ji Pang, Yongchang Chen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Type II cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG II) is a membrane-anchored enzyme expressed mainly in the intestinal mucosa and the brain, and is associated with various physiological or pathological processes. Upregulatio
Externí odkaz:
https://doaj.org/article/bc61b26425444a2fb11510aed07bd309
Autor:
Yue Wang, Ying Li, Liang Wang, Buze Chen, Miaolin Zhu, Chunyi Ma, Chunyan Mu, Aibin Tao, Shibao Li, Lan Luo, Ping Ma, Shuai Ji, Ting Lan
Publikováno v:
Frontiers in Pharmacology; 2024, p1-12, 12p
Autor:
Shaodi Wen, Xiaoyue Du, Yuzhong Chen, Jingwei Xia, Ruotong Wang, Miaolin Zhu, Weiwei Peng, Gianluca Spitaleri, Paul Hofman, Paolo Bironzo, Xin Wang, Bo Shen
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Immunotherapy deeply changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) in the past years. However, the objective response rate (ORR) after immunotherapy is about 20–30% of NSCLC patients. Therefore, identific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88b42be2245ac7a496cec8ef6cafb5df
https://doi.org/10.21037/tlcr-22-300
https://doi.org/10.21037/tlcr-22-300